Recon: Sanofi inks $1.7B deal with Dren Bio for autoimmune therapy; MHRA approves GSK’s twice-yearly asthma treatment

• Trump order blocking state AI laws could slow health AI adoption, leave patients vulnerable (STAT)
• AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment (Reuters)
• Medicare routes $16 billion to insurers to offset high drug costs (STAT)
• Gilead's experimental HIV treatment non-inferior to blockbuster drug in trial (Reuters)
• Moderna Takes on Unusual FDA Request: Do Its Vaccines Cause Long Covid? (Bloomberg)
• US FDA sends warning letters to Walmart, Target for selling recalled baby formula (Reuters)
• US FDA grants priority voucher to J&J's blood cancer treatment (Reuters)

• Europe’s pharma policy shakeup moves forward toward enactment (STAT)
• China has a cheap, quick and quiet way to test novel therapies. Western genetic medicine makers want in (Endpoints)
• UK approves GSK's twice-yearly asthma drug (Reuters)
• UK Doctors Plan Strike This Week After Rejecting Streeting Offer (Bloomberg)
• Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront (Endpoints)

• Areteia Therapeutics, a $425M bet on asthma disorder, to wind down after terminating Phase 3 studies (Endpoints)
• Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research (Reuters)
• Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial (Endpoints)
• Aviceda's geographic atrophy drug fails mid-stage study. Can it do better in Phase 3? (Endpoints)
• Palvella unwraps Phase 2 data for rapamycin gel in rare skin disease (Endpoints)
• InnoCare says Zenas-partnered drug succeeds in China study in form of lupus (Endpoints)
• Immunome's rare tumor drug passes Phase 3 test, could challenge Merck KGaA (Endpoints)
• Sanofi flags second delay to FDA decision on multiple sclerosis drug, shares fall (Reuters)
• Cencora to take majority control of cancer care network OneOncology for $5 billion (Reuters)
• Fosun Plans to Buy Maker of Controversial Alzheimer’s Drug (Bloomberg)
• OpenAI-Backed Chai Discovery Raises $130 Million for AI-Designed Molecules (Bloomberg)
• Argenx Drops After Discontinuing Thyroid Eye Disease Drug Trial (Bloomberg)
• Everything is changing in dementia diagnosis and treatment (STAT)

• Medical Supplier Medline Guides IPO to Upper Half of Price Range (Bloomberg)
• FDA needs more staff, authority to oversee device recalls, watchdog finds (MedTech Dive)
• AtriCure treats first patients with dual PFA/RF system (MedTech Dive)
• Mick Farrell named chair of AdvaMed board (MedTech Dive)
• All Change For Notified Bodies: Moving Towards A More Highly Regulated Future (MedTech Insight)

• As superbug fears grow, sales of antibiotics used in food-producing livestock rose dramatically last year (STAT)
• Explainer: What is lumpy skin disease for cattle and why are French farmers angry? (Reuters)